

UNIVERSITI TEKNOLOGI MARA

***IN VITRO* EVALUATION OF SMALL
MOLECULES INHIBITORY
ACTIVITY AGAINST APOBEC3B
CYTOSINE DEAMINASE ENZYME**

MARYAN MOHAMUD MOHAMED

Thesis submitted in fulfillment
of the requirements for the degree of
Master of Science
(Molecular Biology)

Faculty of Applied Sciences

August 2022

ABSTRACT

Human APOBEC3B (A3B) is a member of the APOBEC3 (A3) family of cytidine deaminases, which function as DNA mutators and restrict viral pathogens and endogenous retrotransposons. APOBEC3B has both C-terminal catalytic (CTD) and N-terminal pseudo-catalytic (NTD) of zinc domains, only the CTD in APOBEC3B has been identified to have enzymatic activity. Even though APOBEC3B has important role in innate immunity, it was also identified as a major source of genetic heterogeneity in several human cancers. Therefore, therapeutic interventions using small molecules in modulating APOBEC3B may represent a strategy for cancer prevention and treatment. In this study, a pharmacoinformatics approach was adopted to narrow down potential chemical compounds against the APOBEC3B enzyme. Virtual screening of 2000 drug-like molecules from the National Cancer Institute (NCI) Development Therapeutics Program (DTP) drug library was performed using docking programs; GOLD and AutoDock/Vina against the X-ray crystallography structure of APOBEC3B (PDB ID: 5TD5). Among the docked compounds, nordracorubin, NSC641233, and raloxifene (RAL) showed the best binding energies towards APOBEC3B on both AutoDock/Vina and GOLD. Several significant interactions were observed between APOBEC3B and the three hits, including hydrogen bonding and pi-pi stacking. The three compounds and aurintricarboxylic acid (ATA); a positive control molecule, were further studied to validate their APOBEC3B inhibitory activities *in vitro* using a Fluorescence Resonance Energy Transfer (FRET) based assay. The three compounds with different concentrations (0.781 - 25 μM) were tested against purified recombinant APOBEC3B protein (80ng/ μL) incubated with ssDNA substrate containing the target cytosine. Among the test compounds, only nordracorubin and raloxifene showed inhibition of APOBEC3B in the FRET assay, while NSC641233 showed no effect against the APOBEC3B enzyme. Nordracorubin exhibited more APOBEC3B inhibitory potency (IC_{50} : $7.92 \pm 0.68 \mu\text{M}$) than raloxifene (IC_{50} : $14.95 \pm 0.52 \mu\text{M}$). Interestingly, there was no statistically significant difference between nordracorubin and ATA, indicating the efficacy of nordracorubin compared with the positive control. In addition, the cytotoxic activity of nordracorubin, raloxifene, ATA, and doxorubicin against MDA-MB-231 breast cancer cells was evaluated using the MTT assay. Nordracorubin showed a higher cytotoxic effect on MDA-MB-231 cell line (IC_{50} : $6.85 \pm 0.58 \mu\text{M}$) than ATA and raloxifene (IC_{50} : 7.92 ± 1.10 and $43.65 \pm 2.25 \mu\text{M}$), respectively. There were no significant differences between the IC_{50} values of nordracorubin and the standard cytotoxic drug. These results suggest that nordracorubin has an important inhibitory activity on APOBEC3B and could be further developed to enhance its efficacy against APOBEC3B in targeting early mutations in the development of precancerous lesions and ultimately prevent chemotherapy resistance.

ACKNOWLEDGEMENT

Firstly, I wish to thank Allah for giving me the opportunity to embark on my Master's and for completing this long and challenging journey successfully. My gratitude and thanks go to my supervisor Prof. Ts. Dr. Mohd Ilham Adenan, who accepted me as his student. His dedication, support, and constant supervision have been great motivation for me to complete my research. I am also very grateful for the financial help I received during my study and his patience in seeing me through this project. My greatest appreciation goes to my co-supervisor Dr Ng Kwok Wen, for his scientific discussion and his guidance throughout this process.

I would also like to thank all the staff and friends at the Institute of Science (IOS) and tissue culture Puncak Alam, especially Mr Yazid and Madam Mastura Ma'ad, for giving me a place and chance to use the equipments there. To my seniors, Nor Atiqah Binti Jusril, Zuriati Zahari, Nelofar, and all my friends; thank you for your guidance and support throughout this project. The kind and friendly atmosphere which they provided enable me to enjoy doing this research.

Finally, I am dedicating this to my parents; Mohamud Mohamed Egal and Aisha Abdul-kadir Hussein, who have been the supportive backbone for the duration of my study. Alhamdulillah.

This study was funded by Research Grant (100-IRMI/GOV 16/6/2) (013/2019)] from Ministry of Agriculture, Malaysia.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	viii
LIST OF FIGURES	ix
LIST OF PLATES	xi
LIST OF SYMBOLS	xii
LIST OF ABBREVIATIONS	xiii
LIST OF NOMENCLATURES	xv
CHAPTER ONE INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statement	4
1.3 Objectives	4
1.4 Significance of the Study	5
1.5 Scope and Limitation	5
CHAPTER TWO LITERATURE REVIEW	6
2.1 The APOBEC Family	6
2.2 APOBEC3 Sub-Family	7
2.2.1 Substrate Specificity of APOBEC3 Deaminases	9
2.2.2 Physiological Function of APOBEC3s	10
2.2.3 APOBEC3B	12
2.3 APOBEC3 Enzymes and Cancer	15
2.3.1 APOBEC3B Enzyme Links to Cancer	18
2.4 Previous Efforts of APOBEC3s Inhibition based on Small Molecules	29
2.5 Identification of APOBEC3 Inhibitors	38

2.5.1	Molecular Docking Approaches	38
2.5.2	Fluorescence Resonance Energy Transfer (FRET) Assay	40
CHAPTER THREE RESEARCH METHODOLOGY		43
3.1	Materials	43
3.1.1	Chemicals and Reagents	43
3.1.2	Equipment	44
3.2	Methods	45
3.2.1	Virtual Screening Techniques	45
3.2.2	Molecular docking and Post-docking Analysis	46
3.2.3	<i>In vitro</i> Deaminase Assay	48
3.2.4	Cell Culture	49
3.2.5	<i>In-vitro</i> Cytotoxicity Assay	50
3.3	Statistical Analysis	51
CHAPTER FOUR RESULTS AND DISCUSSION		53
4.1	<i>In Silico</i> Identification of APOBEC3B Inhibitors from NCI Database	53
4.1.1	The <i>In Silico</i> Interaction Analysis of APOBEC3B and The Small Molecules	55
4.2	Fluorescence Resonance Energy Transfer (FRET) Assay	60
4.2.1	Fluorescence-based Screening of APOBEC3B deaminase activity	60
4.2.2	Dose Response Data for the Selected Compounds	62
4.3	<i>In-vitro</i> Cytotoxicity Assay	65
CHAPTER FIVE CONCLUSION AND RECOMMENDATIONS		69
REFERENCES		71
APPENDICES		96
AUTHOR'S PROFILE		106